Business · 24/04/2006Updated: 10/17/2026 · 1 min read

FDA Corrects Notice on FASLODEX Patent Extension

Summary

The FDA is revising the regulatory review period for FASLODEX after discovering a clerical error in the product's investigational new drug application (IND) effective date, following a request for revision filed by the manufacturer.

Original source language: Federal Register — Food and Drug AdministrationOpen original release →

Add your company to Business Communicator

We monitor business sources and connect attention with companies, profiles and services available in Business Communicator.

Create a free company profile Explore businesses on Business Maps →

Create a free company profile →

Explore insights

Business insights →

Healthcare Business News Global Markets News Trade Regulation News Business Technology News Fintech for Business: Payments & Banking News Supply Chain News

Related business signals

Business · 10/9/2026

Center for Scientific Review Notice of Closed Meetings

The Center for Scientific Review has announced closed meetings for the following review groups: the Neurological Sciences A Study Section and the Neurological Sciences B Study Section.

Read summary →

Business · 9/16/2026

Microbiology Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Pathogen-Agnostic Sequencing

The Food and Drug Administration (FDA) announces a public advisory committee meeting of the Microbiology Devices Panel to discuss pathogen-agnostic sequencing for emergency preparedness and response efforts.

Read summary →

Business · 9/16/2026

Food and Drug Administration Announces Proposed Collection of Information for Reporting of Biological Product Deviations and Human Cells, Tissues, and Cellular and Tissue-Based Product Deviations in Manufacturing

The Food and Drug Administration (FDA) has submitted a proposed collection of information to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

Read summary →

Business · 9/16/2026

Agency Information Collection Request; 30-Day Public Comment Request

The Office of the Secretary (OS), Department of Health and Human Services, submitted an Information Collection Request (ICR) to the Office of Management and Budget (OMB) for review and approval, with a 30-day public comment period.

Read summary →

Business · 10/5/2026

Center for Scientific Review Amends Meeting Notice

The Center for Scientific Review has updated its meeting notice, making the details publicly available.

Read summary →

Business · 9/17/2026

FDA Grants Partial Exemption to Medical Devices

The FDA has finalized a rule exempting certain radiology computer-aided detection and diagnosis devices from premarket notification requirements, following a petition filed in 2025 and denied in 2026.

Read summary →